Sarepta Therapeutics Inc to Discuss Results from 30 mg/kg Cohort of MOMENTUM Study of SRP-5051 for Duchenne Muscular Dystrophy Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Aaron Zachary Welch - Guggenheim Securities, LLC, Research Division - Analyst : Congrats on all the progress. This is Aaron on for Debjit. So could you just comment on how low the potassium dropped in the patient with hypokalemia? And also, is there a supplementation or monitoring plan in place for potassium as well?

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : Maybe on the other potential exon-skipping drugs is, considering this is a more generalistic strategy, how will these findings with the 51 skipping be translatable to skipping of the other 2 targets?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the data. So just to expand on what a couple of them have asked you. But -- can you talk about the cadence of the adverse events? And just how this has factored into your thoughts about dosing higher? I mean if they're more front-end loaded, could you not titrate the dose higher over time? Because obviously, more dystrophin is better. And then just a house-keeping one on patient numbers. I think this is a 6-patient cohort. So when will we get the next 2 patients worth of data?